Here, we present the results from the cohort of patients with advanced cervical cancer. COVID-19 is an emerging, rapidly evolving situation. Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination - Full Text View. COVID-19 is an emerging, rapidly evolving situation. Purpose The KEYNOTE-028 trial (ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma. Methods Patients were treated with pembrolizumab 10 mg/kg every …
You have reached the maximum number of saved studies (100).Please remove one or more studies before adding more.This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccinationAdverse events occurring within 1 month after vaccination.SAEs and NDCMCs occurring within 6 months after vaccination.Subjects with ≥4-fold rise in OPA titers 1 month after vaccination.Subjects with OPA titers ≥ LLOQ 1 month after vaccination.
Descriptive Information; Brief Title ICMJE A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes Official Title ICMJE A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus
You have reached the maximum number of saved studies (100).Please remove one or more studies before adding more.
Patient-Level Summary of Clinical Trial NCT01655225 A Clinical Trial Sponsored by Eli Lilly and Company The Purpose of this Clinical Trial (provided by the Sponsor) The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Plan to Share IPD: No: Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
The study aims to evaluate the 6 month-treatment tolerance defined as the immune related grade 3-4 adverse event-free survival of the combination therapy IT ipilimumab + IV nivolumab.The IV ipilimumab + IV nivolumab (same doses than in Phase I) arm will be used as an internal control to interpret the results obtained in the IT ipilimumab arm.Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to randomization:Female CrCl = [(140 - age in years) x weight in kg x 0.85] / (72 x serum creatinine in mg/dL) Male CrCl = [(140 - age in years) x weight in kg x 1.00] / (72 x serum creatinine in mg/dL) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors - NCT02541604
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma - Full Text View.